Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Bone Marrow Failure: early-phase trial registry

3 of 6 indexed Bone Marrow Failure trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Bone Marrow Failure: 6 US clinical trials tracked, 3 recruiting.

Bone Marrow Failure is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Elixirgen Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition bone-marrow-failure

OPEN 3 | RECR 50% | LATE 0 | EARLY 6 | RANK #2866 | SPON 1

Nearest open-share peer: Achalasia (50% recruiting · 8 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Bone Marrow Failure (this)50%
Open-enrollment share among volume-matched conditions near Bone Marrow Failure

Bone Marrow Failure lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Bone Marrow Failure on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Bone Marrow Failure is recruiting above its size-band peers.

    3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Bone Marrow Failure research.

    Elixirgen Therapeutics accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Bone Marrow Failure trials plan to enrol fewer than 100 people.

    Median target enrolment is 27 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.

  4. Bone Marrow Failure research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4

Named interventions

Most-linked intervention names on Bone Marrow Failure records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Fludarabine Drug
3 trials
Cyclophosphamide Drug
2 trials
Reduced Intensity (Fanconi) Drug
1 trials
Reduced Intensity Drug
1 trials
Full Intensity Drug
1 trials
Full Intensity with TBI Drug
1 trials
EXG34217 Biological
1 trials
Cytokine-treated Veto Cells Biological
1 trials

US sites by state

Facility locations filed on Bone Marrow Failure trials. A trial with sites in several states counts in each.

New York 2 trials
Texas 1 trials
Ohio 1 trials
Minnesota 1 trials
Maryland 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Bone Marrow Failure page

6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bone Marrow Failure condition card totals 6 registered trials; most-linked intervention Fludarabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.